Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives Cigna Coverage for Veristrat

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Cigna for its Veristrat test for guiding therapy in patients with non-small cell lung cancer.

The decision gives Biodesix more than 115 million covered lives for the test, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors. Cigna has 13.3 million US members.

The announcement follows several other recent positive coverage decisions for Veristrat. Last month UnitedHealthcare issued a positive coverage decision for the test, and in April CareFirst Blue Cross Blue Shield issued a positive coverage decision.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.